1,869 results on '"Freeman, Gordon J."'
Search Results
52. The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy
53. Role of PD-1 during effector CD8 T cell differentiation
54. RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism
55. Anti-Programmed Death 1 (PD1)
56. Down-regulation of CTLA-4 by HIV-1 Nef protein.
57. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
58. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
59. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
60. Retinoblastoma protein expression and its predictors in triple-negative breast cancer
61. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
62. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
63. PD-L1-Deficient Mice Show That PD-L1 on T Cells, Antigen-Presenting Cells, and Host Tissues Negatively Regulates T Cells
64. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
65. Proceedings of the third international molecular pathological epidemiology (MPE) meeting
66. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
67. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
68. Molecular Cloning of Porimin, A Novel Cell Surface Receptor Mediating Oncotic Cell Death
69. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model.
70. CD48-Deficient Mice Have a Pronounced Defect in CD4 + T Cell Activation
71. Cyclin DCDK4 kinase destabilizes PD-L1 via cullin 3SPOP to control cancer immune surveillance
72. Attractin (DPPT-L), a Member of the CUB Family of Cell Adhesion and Guidance Proteins, is Secreted by Activated Human T Lymphocytes and Modulates Immune Cell Interactions
73. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
74. Supplementary Table from Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
75. Data from Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
76. Abstract 886: Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects
77. Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
78. Supplementary Figure from Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
79. Supplementary Figures and Tables from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
80. Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
81. Data from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
82. Data from Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
83. Data from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
84. Supplementary Table S2 from Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer
85. Figure S2 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma
86. Supplementary Table S2 from MicroRNA MIR21 and T Cells in Colorectal Cancer
87. Data from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
88. Data from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma
89. Data from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
90. Data from MicroRNA MIR21 and T Cells in Colorectal Cancer
91. Data from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
92. Supplemental Tables 1 and 2 from Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
93. Supplemental Figures 1-4 from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
94. Supplementary Figures 1 through 7, Supplementary Methods from Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
95. Supplementary Tables from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
96. Supp. Movie 3 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
97. Supplementary Table 5 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
98. Supplementary Data from CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
99. Table S1 from In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma
100. Supplemental Figure and Table Legends from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.